TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

No classification published
Location not published
Official notice
Published value
£877,670,570
Submission deadline 17 Apr 2026, 13:00 BST
Lots published2
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026". Published status: complete. Published value: £877,670,570. 2 published lots. Recorded submission deadline: 17 Apr 2026, 13:00 BST. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
Closed
17 Apr 2026, 13:00 BST
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)£877,670,570
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
22.8Bids / Report
7.7% of reports have one bid
Supplier ConcentrationModerate Concentration
Anna FreudTop vendor: 29.6% of attributable value
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 859 active published awards; 13 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Historical Awarded Suppliers With This Authority:
Supplier NameHistoric AwardsAttributable GBP Value
Anna Freud1 win£5,862,540
Anglia Ruskin University1 win£4,809,159
NHS Shared Business Services Limited1 win£4,393,727
Pearson Professional Assessments Limited1 win£4,374,320
Timewise Foundation CIC1 win£166,667
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published21 Jul 2026, 11:16 BST
Last source update21 Jul 2026, 11:16 BST
Recurring procurementNot published
ClassificationNot published
Delivery areaLocation not published
OCIDocds-h6vhtk-051c98
What is being bought
NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
What changed
From the official release history
  1. Official notice release published
    21 Jul 2026, 11:16 BST
  2. Official notice release published
    9 Jul 2026, 15:45 BST
  3. tender value changed
    23 Jun 2026, 12:33 BST
  4. Status changed to complete
    23 Jun 2026, 12:33 BST
  5. Official notice release published
    23 Jun 2026, 12:33 BST
  6. Submission deadline changed to published date
    23 Jun 2026, 12:33 BST
  7. Published value updated to £877,670,570
    17 Mar 2026, 12:14 GMT
  8. Status changed to active
    17 Mar 2026, 12:14 GMT
  9. Official notice release published
    17 Mar 2026, 12:14 GMT
  10. Submission deadline changed to 17 Apr 2026, 13:00 BST
    17 Mar 2026, 12:14 GMT
  11. Official notice release published
    13 Mar 2026, 15:08 GMT
  12. Published value updated to £456,000,000
    13 Jan 2026, 09:57 GMT
  13. Official notice release published
    13 Jan 2026, 09:57 GMT
  14. Official notice release published
    3 Jun 2025, 12:41 BST
  15. Published value updated to £206,835,684
    22 May 2025, 09:34 BST
  16. Status changed to planned
    22 May 2025, 09:34 BST
  17. Official notice release published
    22 May 2025, 09:34 BST
  18. Buyer information updated
    22 May 2025, 09:34 BST
Lots and requirements (2)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #2
    Individual lot title not published
    complete
    Published valueNot published
    The source published no individual title or description for this lot.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    21 Jul 2026, 11:16 BST
  2. Submission deadline
    17 Apr 2026, 13:00 BST
  3. Award active
    Not published · Not published
  4. Award active
    Not published · Not published
  5. Contract active
    Signed 6 Jul 2026, 00:00 BST · £665,389,588
  6. Contract active
    Signed 6 Jul 2026, 00:00 BST · £35,312,548
Commercial outcome and competition
Awards
AVENTIS PHARMA LIMITED t-a Sanofi, Accord UK Ltd, Amgen Ltd, BAYER PLC, BIOGEN IDEC LIMITED, C. S. T. PHARMA LIMITED, CHUGAI PHARMA LIMITED, ELI LILLY & COMPANY LTD, GEDEON RICHTER (UK) LIMITED, GLAXOSMITHKLINE UK LIMITED, LABORATORIES JUVISE PHARMACEUTICALS, MERCK SERONO LIMITED, MILPHARM LIMITED, NAPP PHARMACEUTICALS LTD, NOVO NORDISK
Not published · Not published · active
BIOGEN IDEC LIMITED, SANDOZ LIMITED
Not published · Not published · active
Contracts
Lot 1 - CM/PHR/25/5730/01 - NHS National Branded Tranche B - NOFE & MAE
£665,389,588 · signed 6 Jul 2026, 00:00 BST · active
Contract period: 1 Sept 2026, 00:00 BST — 31 Aug 2028, 23:59 BST
Lot 2 - CM/PHR/25/5730/02 - Natalizumab for London and South of England
£35,312,548 · signed 6 Jul 2026, 00:00 BST · active
Contract period: 1 Sept 2026, 00:00 BST — 31 Aug 2027, 23:59 BST
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-PPON-PDPT-3135-BWWY
View buyer profile
Documents (1)
Official links; attachments are not copied

  • Not published

    tender
    conflictOfInterest
Related procedures (0)
No data
No related procedures published